Literature DB >> 17889960

Heterogeneity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung nodule.

Hirofumi Nakano1, Hiroshi Soda2, Mineyo Takasu3, Nanae Tomonaga1, Hiroyuki Yamaguchi1, Katsumi Nakatomi1, Satoru Fujino4, Tomayoshi Hayashi5, Yoichi Nakamura1, Kazuhiro Tsukamoto3, Shigeru Kohno1.   

Abstract

It has been proposed that stepwise progression occurs from atypical adenomatous hyperplasia (AAH) through bronchioloalveolar carcinoma (BAC) to invasive lung adenocarcinoma. However, the underlying molecular mechanisms have not been identified. We report a patient with a mixed adenocarcinoma of the lung that had different EGFR mutations in the papillary subtype, the acinar subtype, and the surrounding AAH and BAC areas. EGFR mutations may accumulate during tumor progression and lead to heterogeneity of EGFR mutations within the tumor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17889960     DOI: 10.1016/j.lungcan.2007.08.021

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  10 in total

1.  ASCO Provisional Clinical Opinion: Epidermal Growth Factor Receptor Mutation Testing in Practice.

Authors:  Mary Beth Beasley; Daniel T Milton
Journal:  J Oncol Pract       Date:  2011-04-25       Impact factor: 3.840

Review 2.  Surgery for NSCLC in the era of personalized medicine.

Authors:  Tetsuya Mitsudomi; Kenichi Suda; Yasushi Yatabe
Journal:  Nat Rev Clin Oncol       Date:  2013-02-26       Impact factor: 66.675

3.  EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.

Authors:  Zhi-Yong Chen; Wen-Zhao Zhong; Xu-Chao Zhang; Jian Su; Xue-Ning Yang; Zhi-Hong Chen; Jin-Ji Yang; Qing Zhou; Hong-Hong Yan; She-Juan An; Hua-Jun Chen; Ben-Yuan Jiang; Tony S Mok; Yi-Long Wu
Journal:  Oncologist       Date:  2012-06-06

4.  Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer.

Authors:  Katsuhiko Shimizu; Takuro Yukawa; Yuji Hirami; Riki Okita; Shinsuke Saisho; Ai Maeda; Koichiro Yasuda; Masao Nakata
Journal:  Target Oncol       Date:  2012-12-05       Impact factor: 4.493

Review 5.  Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications.

Authors:  Federica Zito Marino; Roberto Bianco; Marina Accardo; Andrea Ronchi; Immacolata Cozzolino; Floriana Morgillo; Giulio Rossi; Renato Franco
Journal:  Int J Med Sci       Date:  2019-06-10       Impact factor: 3.738

6.  Clinicopathologic and molecular characteristics of lung adenocarcinoma arising in young patients.

Authors:  Lucia Kim; Kyu Ho Kim; Yong Han Yoon; Jeong Seon Ryu; Suk Jin Choi; In Suh Park; Jee Young Han; Joon Mee Kim; Young Chae Chu
Journal:  J Korean Med Sci       Date:  2012-08-22       Impact factor: 2.153

7.  Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing.

Authors:  Luisella Righi; Alessandra Cuccurullo; Simona Vatrano; Susanna Cappia; Daniela Giachino; Paolo De Giuli; Mara Ardine; Silvia Novello; Marco Volante; Giorgio V Scagliotti; Mauro Papotti
Journal:  BMC Cancer       Date:  2013-03-13       Impact factor: 4.430

8.  Malignant pleural effusion supernatants are substitutes for metastatic pleural tumor tissues in EGFR mutation test in patients with advanced lung adenocarcinoma.

Authors:  Dan Liu; Yachao Lu; Zhenli Hu; Ning Wu; Xiaomeng Nie; Yang Xia; Yiping Han; Qiang Li; Guanshan Zhu; Chong Bai
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

9.  Analysis and comparison of somatic mutations in paired primary and recurrent epithelial ovarian cancer samples.

Authors:  Yong-Man Kim; Shin-Wha Lee; Sung-Min Chun; Dae-Yeon Kim; Jong-Hyeok Kim; Kyu-Rae Kim; Young-Tak Kim; Joo-Hyun Nam; Paul van Hummelen; Laura E MacConaill; William C Hahn; Se Jin Jang
Journal:  PLoS One       Date:  2014-06-17       Impact factor: 3.240

10.  Detection of plasma T790M mutation after the first generation EGFR-TKI resistance of non-small cell lung cancer in the real world.

Authors:  Haiyan Li; Jinwei Wang; Guojing Zhang; Yuping Li; Ling Lin; Haihua Yang; Jingjing Zhou; Lingna Zhang; Dongqing Lv
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 3.005

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.